At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 120 enrolled
Drug / intervention
Vi-CRM197 vaccine +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Controlled, Observer Blind, Single Center Study of the Safety, Reactogenicity and Immunogenicity of the NVGH Glycoconjugate Vaccine Against S. Typhi in Children, Older Infants and Infants
In Brief
A Phase 2 clinical trial evaluating Vi-CRM197 vaccine, Pneumococcal conjugate vaccine, and 1 other intervention for Typhoid Fever. Completed, enrolled 120 participants across 1 site.
Detailed Summary
This phase 2 trial is aimed to obtain information on the safety and immunogenicity of the Vi-CRM197 in children and infants from various age groups in the Philippines where Typhoid Fever is highly endemic and an efficacious vaccine against this disease is very much needed.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTyphoid Fever
CountriesPhilippines
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedSep 2011
Enrollment StartOct 2011
Primary CompletionAug 2012
TodayJul 2026
First PostedSep 20, 2011
Enrollment StartOct 1, 2011
Primary CompletionAug 1, 2012
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 14.8 years ago
Interventions
Vi-CRM197 vaccinebiological
Pneumococcal conjugate vaccinebiological
Vi Polysaccharide (PS) vaccinebiological